Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mustang BioMBIO -0.21%30 EV-to-FCF is 2.51 as of Jul. 14, 2026, which is 146% above its 10-year median of 1.02. GuruFocus rates MBIO with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 335 Biotechnology companies, Mustang Bio ranks better than 70.75% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mustang Bio's Enterprise Value is $-12.25 Mil.
Mustang Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.88 Mil. Therefore, Mustang Bio's EV-to-FCF for today is 2.51.
The historical rank and industry rank for Mustang Bio's EV-to-FCF or its related term are showing as below:
MBIO'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.69 Med: 1.02 Max: 2.55
Current: 2.51
During the past 11 years, the highest EV-to-FCF of Mustang Bio was 2.55. The lowest was -4.69. And the median was 1.02.
MBIO's EV-to-FCF is ranked better than 70.75% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs MBIO: 2.51
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mustang Bio's PE Ratio (TTM) for today is calculated as:
Mustang Bio's share price for today is $0.6624.
Mustang Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mustang Bio EV-to-FCF Related Terms
Mustang Bio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Mustang Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mustang Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mustang Bio EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mustang Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mustang Bio's EV-to-FCF falls into.
Mustang Bio's current Enterprise Value is $-12.25 Mil.
Mustang Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mustang Bio (MBIO) has a EV-to-FCF of 2.51 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mustang Bio and its competitors. This is 146% above median its historical median of 1.02. According to the industry distribution chart, Mustang Bio ranks #98 out of 335 companies in the Biotechnology industry, placing it in the top 29.3%.
Is Mustang Bio's EV-to-FCF too high?
Mustang Bio's current EV-to-FCF of 2.51 is 146% above median its 10-year median of 1.02. The Biotechnology industry median EV-to-FCF is 15.34. Mustang Bio's value of 2.51 is 83.6% below this industry median. Based on the distribution chart, Mustang Bio ranks #98 out of 335 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mustang Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Mustang Bio's EV-to-FCF compare to ELAB and DRMA?
According to the Biotechnology industry distribution chart, Mustang Bio ranks #98 out of 335 companies for EV-to-FCF. This puts Mustang Bio in the upper half of its industry. The industry median EV-to-FCF is 15.34. Mustang Bio's value of 2.51 is 83.6% below this benchmark. While the company's 10-year median is 1.02 vs. the industry median of 15.34, Mustang Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mustang Bio's current EV-to-FCF of 2.51 is 83.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mustang Bio and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mustang Bio's current EV-to-FCF is 2.51, which is 146% above median its own 10-year median of 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mustang Bio stock overvalued right now?
Mustang Bio (MBIO) has a current EV-to-FCF of 2.51. The current EV-to-FCF is 2.51, which is 146% above median its 10-year median of 1.02 and 83.6% below the Biotechnology industry median of 15.34. Mustang Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Mustang Bio (MBIO), the current EV-to-FCF is 2.51 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
30GF Score
Get the complete analysis for MBIO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBIO has been successfully added to your 
